Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | ECE1 | P42892 | 4/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL926632 | 0.89 | MAOB (0.51) | MAOBTP53MAPTECE1ROCK2 | |
| SCHEMBL4655386 | 0.88 | ECE1 (0.51) | MAOBECE1ROCK1PTGDR2PPARG | |
| SCHEMBL3579347 | 0.88 | ECE1 (0.51) | MAOBECE1PTGDR2F10 | |
| SCHEMBL4655292 | 0.88 | MAOB (0.50) | MAOBTP53MAPTKDM4EMEN1 | |
| SCHEMBL4655390 | 0.86 | MAOB (0.50) | MAOBKDM4EECE1PTGDR2PPARG | |
| SCHEMBL4655266 | 0.86 | ECE1 (0.56) | MAOBMAPTKDM4EECE1PTGDR2 | |
| SCHEMBL4655318 | 0.86 | ECE1 (0.51) | MAOBMAPTKDM4EECE1PTGDR2 | |
| SCHEMBL2811019 | 0.85 | RAB9A (0.55) | MAOBTP53MAPTKDM4ECYP1A2 | |
| SCHEMBL2813234 | 0.85 | MAOB (0.52) | MAOBTP53MAPTKDM4EMEN1 | |
| SCHEMBL4655389 | 0.85 | MAOB (0.47) | MAOBTP53ECE1PTGDR2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1912644-B1 | N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF | SANOFI AVENTIS (FR) | 2009-12-16 | — | — | EP | claimed |
| CN-101247808-B | N- (arylalkyl) -1H-pyrrolopyridine-2-carboxamide derivatives and their preparation | SANOFI AVENTIS | 2014-08-27 | — | — | CN | disclosed |
| US-20100249183-A1 | THERAPEUTIC USE OF N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | US | disclosed |
| US-7763636-B2 | N-(arylalkyl)-1H-pyrrolopyridine-2-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-07-27 | — | — | US | disclosed |
| EP-1912644-B1 | N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF | SANOFI AVENTIS (FR) | 2009-12-16 | — | — | EP | disclosed |
| CN-101247808-A | N- (arylalkyl) -1H-pyrrolopyridine-2-carboxamide derivatives, their preparation and their therapeutic use | SANOFI AVENTIS (FR) | 2008-08-20 | — | — | CN | disclosed |
| US-20080125459-A1 | N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-05-29 | — | — | US | disclosed |
| EP-1912644-A2 | N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF | Sanofi-Aventis (FR) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007010138-A2 | N(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125459-A1 | N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | CYP3A5, ZYX, ZDHHC2 | MAOB 193/4885TP53 3733/4885MAPT 4141/4885 |
| US-20100249183-A1 | THERAPEUTIC USE OF N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES | ZDHHC2, ZYX, GLS2 | MAOB 534/4885TP53 2476/4885MAPT 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.